LexAurum Advisors LLC Sells 12,755 Shares of Precigen, Inc. $PGEN

LexAurum Advisors LLC trimmed its position in shares of Precigen, Inc. (NASDAQ:PGEN) by 1.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 672,543 shares of the biotechnology company’s stock after selling 12,755 shares during the period. LexAurum Advisors LLC’s holdings in Precigen were worth $955,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of PGEN. Parkman Healthcare Partners LLC bought a new position in Precigen during the first quarter valued at $4,755,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Precigen by 3.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company’s stock worth $16,801,000 after acquiring an additional 410,595 shares during the period. Inspire Investing LLC bought a new position in shares of Precigen in the first quarter worth $350,000. Nuveen LLC bought a new position in shares of Precigen in the first quarter worth $275,000. Finally, Mill Creek Capital Advisors LLC boosted its holdings in shares of Precigen by 131.8% in the first quarter. Mill Creek Capital Advisors LLC now owns 255,000 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 145,000 shares during the period. 33.51% of the stock is owned by institutional investors.

Insider Buying and Selling at Precigen

In other news, Director Nancy H. Agee purchased 15,000 shares of the stock in a transaction on Thursday, September 4th. The shares were acquired at an average price of $4.60 per share, for a total transaction of $69,000.00. Following the completion of the transaction, the director directly owned 217,841 shares of the company’s stock, valued at approximately $1,002,068.60. This trade represents a 7.39% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CFO Harry Jr. Thomasian purchased 8,284 shares of the stock in a transaction on Thursday, September 25th. The shares were purchased at an average price of $3.62 per share, for a total transaction of $29,988.08. Following the transaction, the chief financial officer directly owned 465,694 shares of the company’s stock, valued at approximately $1,685,812.28. This represents a 1.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 52,221 shares of company stock worth $207,667 over the last 90 days. Corporate insiders own 47.10% of the company’s stock.

Precigen Stock Performance

Shares of PGEN stock opened at $3.63 on Tuesday. Precigen, Inc. has a 52-week low of $0.65 and a 52-week high of $5.22. The company has a market capitalization of $1.08 billion, a PE ratio of -8.64 and a beta of 1.82. The business’s fifty day moving average is $3.15 and its 200 day moving average is $2.08.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.The company had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.67 million. On average, sell-side analysts forecast that Precigen, Inc. will post -0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PGEN shares. JPMorgan Chase & Co. raised Precigen from an “underweight” rating to a “neutral” rating in a report on Friday, August 15th. HC Wainwright reaffirmed a “buy” rating and issued a $8.50 price target on shares of Precigen in a report on Tuesday, August 19th. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a report on Tuesday, August 19th. JMP Securities raised their price target on Precigen from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 19th. Finally, Wall Street Zen raised Precigen from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.25.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.